Visterra registers $69 million of stock for initial public offering

Leerink Partners and Stifel, Needham and Wedbush PacGrow will assist

By Devika Patel

Knoxville, Tenn., Jan. 5 – Visterra, Inc. will price its initial public sale of common stock with a 30-day greenshoe, according to a Form S-1 filed Tuesday with the Securities and Exchange Commission. The company has registered up to $69 million of stock.

Leerink Partners and Stifel are the bookrunners, and Needham & Co. and Wedbush PacGrow are the co-managers.

Proceeds will be used for manufacturing costs, clinical trials, research, preclinical development, IND-enabling studies, process development and manufacturing, working capital, debt service and other general corporate purposes.

The biopharmaceutical company is based in Cambridge, Mass. The company intends to list its common stock on the Nasdaq stock exchange under the symbol “VIST.”

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.